{"slideshow_credits": null, "snippet": "The latest study of alirocumab, a potentially powerful cholesterol fighter, appears to bolster previous results that it cut cholesterol levels by about half in a clinical trial.", "abstract": "Latest study of alirocumab, potentially powerful lipid-lowering drug being developed by Sanofi and Regeneron Pharmaceuticals, appears to bolster previous results that it cut cholesterol levels by about half in a clinical trial.", "section_name": "Business Day", "print_page": "10", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/10/16/business/early-promise-in-drug-trial-for-fighting-cholesterol.html", "lead_paragraph": "The latest study of alirocumab, a potentially powerful cholesterol fighter, appears to bolster previous results that it cut cholesterol levels by about half in a clinical trial.", "headline": {"main": "Early Promise in Drug Trial for Fighting Cholesterol", "print_headline": "Early Promise In Drug Trial For Fighting Cholesterol"}, "_id": "525e1d5f38f0d819897433da", "word_count": "370", "multimedia": [], "pub_date": "2013-10-16T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Statins (Cholesterol-Lowering Drugs)", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Regeneron Pharmaceuticals Inc", "name": "organizations", "is_major": "Y", "rank": "5"}, {"value": "Cholesterol", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Sanofi SA", "name": "organizations", "is_major": "Y", "rank": "6"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "News"}